Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
topic_facet:"Medical Condition: Rheumatoid arthritis MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Rheumatoid+arthritis+MedDRA+version%3A+9.1Level%3A+LLTClassification+code+10039073Term%3A+Rheumatoid+arthritis%22&lookfor=%22Arthritis%22&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Rheumatoid+arthritis+MedDRA+version%3A+9.1Level%3A+LLTClassification+code+10039073Term%3A+Rheumatoid+arthritis%22&lookfor=%22Arthritis%22&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Rheumatoid+arthritis+MedDRA+version%3A+9.1Level%3A+LLTClassification+code+10039073Term%3A+Rheumatoid+arthritis%22&lookfor=%22Arthritis%22&type=AllFields
PubPharm (136)
1
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic : A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
2
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic : A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study of R935788 in Patients with Rheumatoid Arthritis Who Have Failed at Least One Biologic
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
3
A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis : A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis : A Phase IIIb, open-label, run-in and double-blind, placebo-controlled, randomized study to evaluate the safety and efficacy of certolizumab pegol administered concomitantly with stable-dose methotrexate in patients with active rheumatoid arthritis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate - Atacicept in anti-TNF alfa-naïve subjects with RA : A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate - Atacicept in anti-TNF alfa-naïve subjects with RA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate - Atacicept in anti-TNF alfa-naïve subjects with RA : A randomised, double-blind, placebo controlled, multi-centre phase II study of atacicept in anti- TNF alfa-naïve patients with moderate to severely active rheumatoid arthritis and an inadequate response to methotrexate - Atacicept in anti-TNF alfa-naïve subjects with RA
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy : Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
8
Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy : Phase 2, Dose-Ranging Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
9
Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy. : Extension Phase of the Multi-National Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
10
An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis : An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Patients with Rheumatoid Arthritis
enthalten in:
WHO International Clinical Trials Registry Platform
| 2021
Wird geladen...
1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Thema: Medical Condition: Rheumatoid arthritis MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
Medienart
136
Aufsätze
136
E-Artikel
136
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
136
610
Medical Condition: Rheumatoid arthritis MedDRA ...
136
Study Type: Interventional
134
Recruitment Status: Not yet recruiting
16
Phase: Phase 3
12
Phase: Phase 2
2
Recruitment Status: Authorised-recruitment may ...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
22
2020-
114
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
134
Englisch
2
Italienisch
Haven't found what you're looking for?
Wird geladen...